November 1, 2023 by Chain Drug Review
CVS, third quarter
Featured Articles, Leading Headlines

WOONSOCKET, R.I. — CVS Health topped Wall Street’s estimates for third quarter revenue and earnings. Adjusted earnings per share of $2.21 exceeded analysts’ predicted $2.13, while revenue of $89.76 billion beat the forecast of $88.2 billion. “Our colleagues helped us deliver another quarter of positive results across our business areas,” said president and CEO Karen
August 2, 2023 by Chain Drug Review
CVS, second quarter
Business, Featured Articles, Leading Headlines, Retail News

WOONSOCKET, R.I. — CVS Health topped Wall Street’s estimates for the top and bottom lines for the second quarter ended June 30. Revenue, driven by growth across segments, rose 10.3% to $88.9 billion, exceeding analysts’ forecast of an $86.45 billion. While adjusted earnings dipped 12.6% from the year-ago period to $2.21 per share, they beat
June 14, 2023 by Chain Drug Review
Constellation, CVS, renewable energy
Leading Headlines, Retail News

WOONSOCKET, R.I. — CVS Health will purchase zero-emission, renewable energy from Constellation Energy Corp. equivalent to the annual electricity use of its 147 stores in Michigan. Through a 12-year agreement beginning in April 2025, CVS will buy energy and renewable energy certificates (RECs) from Swift Current Energy’s Double Black Diamond Solar Project in Illinois. This
June 12, 2023 by Chain Drug Review
CVS, Wier
Leading Headlines, Retail News

WOONSOCKET, R.I. _ Michael Wier has been promoted to vice president of store brands at CVS Health. He had been executive director – divisional merchandise manager for consumer health and wellness since August 2020. “In this new role, I am looking forward to collaborating with our exceptional internal and external partners,” Wier wrote on LinkedIn.
May 3, 2023 by Chain Drug Review
CVS, first quarter
Featured Articles, Leading Headlines

WOONSOCKET, R.I. — CVS Health posted first quarter sales and earnings that topped Wall Street’s forecasts. Revenue for the period ended March 31 rose 11% to $85.3 billion, exceeding analysts’ projected $80.79 billion. Adjusted earnings of $2.20 per share beat the average estimate of $2.09. The strong showing notwithstanding, the company lowered its outlook for
February 8, 2023 by Chain Drug Review
CVS, fourth quarter
Featured Articles, Leading Headlines

WOONSOCKET, R.I. — CVS Health topped analysts’ expectations for fourth-quarter sales and earnings, led by strong insurance and retail results. Earnings per share for the three months ended Dec. 31 rose 0.5% from the year-ago period to $1.99 on revenue of $83.8 billion (up 9.5%). Wall Street had projected adjusted EPS of $1.92 on revenue
January 27, 2023 by Chain Drug Review
CVS, Walmart to cut pharmacy hours amid labor concerns
Leading Headlines, Pharmacy, Retail News

NEW YORK — CVS Health and Walmart announced that they will be reducing pharmacy hours to address the ongoing pharmacist shortage, The Wall Street Journal reported Friday. CVS plans to cut or shift operating hours at about two-thirds of its 9,000-strong U.S. network in March, while Walmart intends to close most of its nearly 4,600
January 4, 2023 by Chain Drug Review
abortion pills, CVS, Walgreens
Leading Headlines, Pharmacy, Retail News

NEW YORK — With family planning rights under major threat in several states, the Food and Drug Administration (FDA) announced this week a move to expand access to abortion. Now chains such as CVS and Walgreens will be able to sell abortion pills to those with prescriptions. The FDA gave the green light to mifepristone
December 19, 2022 by Chain Drug Review
CVS, Walgreens
Leading Headlines, Pharmacy, Retail News

NEW YORK— Both CVS and Walgreens are limiting how many children’s pain and fever medications customers can buy — the latest sign that pharmacies are struggling to keep up with demand for basic cold and flu remedies, as respiratory illnesses spike nationwide. CVS is limiting customers to a “two product limit on all children’s pain
December 12, 2022 by Chain Drug Review
CVS, Walgreens announce $10B opioid settlement
Leading Headlines, Pharmacy

NEW YORK — According to published reports, CVS and Walgreens both announced that they have agreed to pay state and local governments a combined total of more than $10 billion to settle lawsuits over the toll of opioids and now requesting by Dec. 31 whether states are accepting the deals. States announced final details Monday
December 5, 2022 by Chain Drug Review
CVS
Leading Headlines, Pharmacy

NEW YORK — CVS Health is now experimenting with a new system that will help pharmacists to fill prescriptions remotely as the drugstore chain faces staff shortages and attempts to deliver additional medical services, according to an article in The Wall Street Journal. The company has implemented the system at approximately 8,000 of more than
December 2, 2022 by Chain Drug Review
CVS, CVS completes rollout of time delay safes in 13 states
Leading Headlines, Pharmacy, Retail News

WOONSOCKET, R.I. – Amidst a busy holiday shopping season and as part of an ongoing commitment to support law enforcement and help build safer communities, CVS Health announced the installation of time delay safe technology in 800 CVS Pharmacy locations — including those in Target stores — in 13 states across the U.S. The states
November 17, 2022 by Chain Drug Review
CVS
Leading Headlines, Retail News

WOONSOCKET, R.I. — CVS Health announced a $14.3 million investment with Chief Seattle Club and Raymond James Affordable Housing Investments to build 120 affordable housing units in Seattle, Washington as part of the company’s commitment to advancing health equity by addressing social determinants of health at the local level. “When people have access to high-quality
November 2, 2022 by Chain Drug Review
CVS, Karen Lynch, Opioid, third quarter
Featured Articles, Leading Headlines

WOONSOCKET, R.I. — CVS Health easily beat analysts’ sales and earnings estimates for the third quarter and again raised its full year guidance. The company reported adjusted earnings per share $2.09 on revenue of $81.16 billion, which climbed 10% from a year earlier. Wall Street had expected adjusted EPS of $1.99 on revenue of $76.75